Hawryluk P. Kent
SEC CIK 1673991 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| MBX | MBX Biosciences, Inc. | Pres, CEO, Dir | 727.7K | $1.33M | $17.9K | 9 | 2024-09-16 | 2026-05-06 |
Most active insiders at MBX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | FHMLS X, L.P. | 10% | $12.00M | — |
| 2 | Azoulay Salomon | Chief Medical Off | — | $2.72M |
| 3 | Hawryluk P. Kent | Pres, CEO, Dir | $798.4K | $17.9K |
| 4 | Hoerter Steven L. | Pres, CEO, Dir | $265.0K | — |
| 5 | Bartram Richard | CFO | — | — |
| 6 | Smither John W | CFO | — | — |
Transactions 9
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-08 16:00 | 2026-05-06 | MBX | MBX Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO, Dir | S - Sale | $29.54 | -607 | 727.7K | -0.1% | -$17.9K | |
| I | 2026-03-16 | 2026-03-13 | MBX | MBX Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO, Dir | P - Purchase | $28.41 | +18.5K | 486.8K | +4% | +$525.6K |
| D | 2026-02-27 | 2026-02-26 | MBX | MBX Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO, Dir | M - OptEx | $16.00 | +28.8K | 728.3K | +4% | +$460.3K |
| D | 2026-02-03 | 2026-02-02 | MBX | MBX Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO, Dir | A - Grant | $0.00 | +35.2K | 699.5K | +5% | $0 |
| D | 2025-10-28 | 2025-10-24 | MBX | MBX Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO, Dir | M - OptEx | $3.25 | +182.9K | 664.3K | +38% | +$594.3K |
| I | 2025-10-21 | 2025-10-20 | MBX | MBX Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO, Dir | P - Purchase | $13.64 | +20.0K | 468.3K | +4% | +$272.8K |
| DI | 2025-02-05 | 2025-02-04 | MBX | MBX Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO, Dir | P - Purchase | $10.69 | +50.0K | 448.3K | +13% | +$534.5K |
| D | 2024-09-17 | 2024-09-16 | MBX | MBX Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO, Dir | C - Cnv Deriv | — | +283.8K | 481.4K | +144% | — |
| DI | 2024-09-17 | 2024-09-16 | MBX | MBX Biosciences, Inc. | Hawryluk P. Kent | Pres, CEO, Dir | C - Cnv Deriv | — | +115.9K | 398.3K | +41% | — |
Purchase Sale Sale after option exercise All abbreviations